ReShape Lifesciences Inc. (RSLS)
NASDAQ: RSLS
· Real-Time Price · USD
3.92
0.72 (22.50%)
At close: Aug 14, 2025, 3:59 PM
ReShape Lifesciences Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 1.11M | 1.8M | 2.29M | 1.97M | 1.94M | 1.98M | 2.15M | 2.25M | 2.29M | 3.11M | 2.8M | 2.89M | 2.44M | 3.14M | 3.71M | 3.53M | 3.22M |
Cost of Revenue | 432K | 486K | 853K | 831K | 779K | 140K | 867K | 1.06M | 1.06M | 1.51M | 697K | 1.01M | 1.22M | 1.37M | 1.57M | 1.38M | 937K |
Gross Profit | 681K | 1.32M | 1.44M | 1.13M | 1.17M | 1.84M | 1.29M | 1.19M | 1.22M | 1.6M | 2.1M | 1.88M | 1.22M | 1.78M | 2.13M | 2.15M | 2.28M |
Operating Income | -2.21M | -643K | -1.76M | -2.05M | -2.21M | -1.9M | -3.1M | -3.98M | -5.63M | -4.71M | -12.3M | -9.24M | -8.4M | -35.56M | -14.98M | -3.7M | -2.26M |
Interest Income | n/a | 1K | n/a | 4K | n/a | 17K | 5K | 9K | n/a | n/a | 31K | 14K | 1K | n/a | n/a | n/a | n/a |
Pretax Income | 1.48M | -1.76M | -1.57M | -1.58M | -2.18M | -1.67M | -3.53M | -3.49M | -2.65M | -16.48M | -12.55M | -9.44M | -8.37M | -35.59M | -17.73M | -3.87M | -4.85M |
Net Income | 1.47M | -1.76M | -1.58M | -1.59M | -2.19M | -1.7M | -3.53M | -3.49M | -2.66M | -16.61M | -12.19M | -9.44M | -8.21M | -35.46M | -17.7M | -3.9M | -4.87M |
Selling & General & Admin | 2.16M | 1.44M | 2.8M | 2.79M | 2.89M | 3M | 3.85M | 4.62M | 6.4M | 5.87M | 6.39M | 10M | 8.87M | 8.3M | 15.55M | 5.75M | 3.97M |
Research & Development | 364K | 521K | 399K | 399K | 484K | 739K | 542K | 581K | 453K | 441K | 583K | 747K | 748K | 277K | 1.57M | 103K | 571K |
Other Expenses | 367K | n/a | n/a | n/a | 25K | n/a | n/a | 6K | 2K | 2K | n/a | -1K | 11K | n/a | n/a | n/a | n/a |
Operating Expenses | 2.89M | 1.96M | 3.2M | 3.19M | 3.38M | 3.74M | 4.39M | 5.2M | 6.86M | 6.31M | 6.97M | 10.75M | 9.62M | 8.58M | 17.12M | 5.86M | 4.54M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 5K | 3.99M | n/a | n/a | n/a | 28K | 33K | 172K | 599K |
Selling & Marketing Expenses | 529K | 583K | 719K | 670K | 1.02M | 1.4M | 1.79M | 2.18M | 2.18M | 2.1M | 2.6M | 4.64M | 4.71M | 2.98M | 3.5M | 1.44M | 1.25M |
Cost & Expenses | 3.32M | 2.45M | 4.05M | 4.02M | 4.15M | 3.88M | 5.26M | 6.26M | 7.92M | 7.82M | 7.67M | 11.76M | 10.84M | 9.95M | 18.69M | 7.23M | 5.48M |
Income Tax Expense | 7K | 5K | 6K | 15K | 14K | 31K | 3K | 4K | 14K | 131K | -363K | 9K | -157K | -129K | -30K | 28K | 25K |
Shares Outstanding (Basic) | 3.11K | 515.57K | 508.85K | 434.87K | 404.43K | 404.43K | 59.53K | 56.02K | 29.45K | 8.08K | 7.78K | 6.66K | 6.39K | 6.16K | 5.89K | 1.57K | 1.35K |
Shares Outstanding (Diluted) | 3.11K | 515.57K | 508.85K | 434.87K | 404.43K | 404.43K | 59.53K | 56.02K | 29.45K | 8.08K | 7.78K | 6.66K | 6.4K | 6.16K | 5.89K | 1.57K | 1.35K |
EPS (Basic) | 474.50 | -1.63 | -3.11 | -3.67 | -5.42 | -4.2 | -59.16 | -62.64 | -90.48 | -2.06K | -1.57K | -1.42K | -1.29K | -5.76K | -3K | -2.48K | -3.6K |
EPS (Diluted) | 474.50 | -1.63 | -3.11 | -3.67 | -5.42 | -4.2 | -59.16 | -62.64 | -90.48 | -2.06K | -1.57K | -1.42K | -1.28K | -5.76K | -3K | -2.48K | -3.6K |
EBITDA | -1.83M | -637K | -1.76M | -2.05M | -2.2M | -1.89M | -3.05M | -3.96M | -5.58M | -15.81M | -4.33M | -8.32M | -7.56M | -35M | -14.44M | -3M | -4M |
EBIT | -1.84M | -642K | -1.76M | -2.05M | -2.21M | -1.9M | -3.1M | -4.01M | -5.63M | -16.32M | -4.87M | -9.57M | -8.37M | -35.56M | -14.98M | -3.7M | -4.17M |
Depreciation & Amortization | 4K | 5K | 5K | 6K | 6K | 7K | 50K | 49K | 48K | 515K | 543K | 545K | 550K | 555K | 548K | 702K | 166K |